​

Esperion Therapeutics (ESPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ESPR Stock Forecast

Esperion Therapeutics (ESPR) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 196.05% increase from the last price of $3.04.

$1 $2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $3.04

ESPR Stock Rating

Esperion Therapeutics stock's rating consensus is Hold, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (37.50%), 13 Hold (54.17%), 2 Sell (8.33%), and 0 Strong Sell (0.00%).

Hold
Total 24 2 13 9 0 Strong Sell Sell Hold Buy Strong Buy

ESPR Price Target Upside V Benchmarks

TypeNameUpside
StockEsperion Therapeutics196.05%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks18.82%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$9.00$8.50
Last Closing Price$3.04$3.04$3.04
Upside/Downside-196.05%179.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25322-18
Sep, 25322-18
Aug, 25222-17
Jul, 25222-17
Jun, 25222-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 25, 2025Kristen KluskaCantor Fitzgerald$9.00$2.56251.56%196.05%
Dec 17, 2024Kristen KluskaCantor Fitzgerald$8.00$3.04163.16%163.16%
May 04, 2022Serge BelangerNeedham$12.00$6.5383.77%294.74%
May 04, 2021Derek ArchilaWells Fargo$20.00$25.59-21.84%557.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 25, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 17, 2024Cantor FitzgeraldOverweightinitialise
Oct 03, 2024H.C. WainwrightBuyBuyhold
Jul 01, 2024H.C. WainwrightBuyBuyhold
Jun 20, 2024Bank of America SecuritiesBuyUnderperformdowngrade
May 22, 2024H.C. WainwrightBuyBuyhold
Jun 15, 2023BarclaysOverweightinitialise
Jun 15, 2023Cowen & Co.Buyupgrade
Jun 15, 2023Bank of America SecuritiesBuyupgrade
Mar 16, 2023NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.05$-11.03$-4.33$-2.03$-0.28----
Avg Forecast$-5.10$-10.05$-3.62$-2.03$-0.30$-0.01$0.03$0.48$0.74
High Forecast$-3.83$-7.54$-2.80$-1.88$-0.26$0.07$0.89$0.88$0.91
Low Forecast$-7.81$-15.39$-5.55$-2.15$-0.33$-0.16$-0.54$0.01$0.26
Surprise %18.63%9.75%19.61%--6.67%----

Revenue Forecast

$50M $170M $290M $410M $530M $650M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$227.55M$78.45M$75.47M$116.33M$332.31M----
Avg Forecast$230.35M$77.81M$77.23M$112.75M$327.44M$343.39M$347.09M$448.57M$536.80M
High Forecast$324.61M$109.65M$108.78M$116.53M$335.81M$404.26M$347.09M$448.57M$629.02M
Low Forecast$186.06M$62.85M$63.70M$106.52M$316.94M$170.69M$347.08M$448.57M$265.59M
Surprise %-1.22%0.82%-2.28%3.18%1.49%----

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-166.19M$-318.82M$-287.82M$-209.25M$-51.74M----
Avg Forecast$-212.30M$-257.51M$-290.64M$-209.25M$-30.47M$-4.89M$-3.40M$45.88M$76.64M
High Forecast$-140.98M$-206.01M$-232.51M$-167.40M$-27.20M$6.73M$91.42M$90.73M$93.76M
Low Forecast$-283.62M$-309.01M$-348.76M$-251.10M$-33.73M$-16.52M$-55.92M$1.03M$26.30M
Surprise %-21.72%23.81%-0.97%-69.85%----

ESPR Forecast FAQ

Is Esperion Therapeutics stock a buy?

Esperion Therapeutics stock has a consensus rating of Hold, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 13 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Esperion Therapeutics is a neutral investment for most analysts.

What is Esperion Therapeutics's price target?

Esperion Therapeutics's price target, set by 24 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 196.05% change from the previous closing price of $3.04.

How does Esperion Therapeutics stock forecast compare to its benchmarks?

Esperion Therapeutics's stock forecast shows a 196.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (18.82%).

What is the breakdown of analyst ratings for Esperion Therapeutics over the past three months?

  • October 2025: 37.50% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 12.50% Strong Sell.
  • September 2025: 37.50% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 12.50% Strong Sell.
  • August 2025: 28.57% Strong Buy, 28.57% Buy, 28.57% Hold, 0% Sell, 14.29% Strong Sell.

What is Esperion Therapeutics’s EPS forecast?

Esperion Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.01, marking a -96.43% decrease from the reported $-0.28 in 2024. Estimates for the following years are $0.03 in 2026, $0.48 in 2027, and $0.74 in 2028.

What is Esperion Therapeutics’s revenue forecast?

Esperion Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $343.39M, reflecting a 3.33% increase from the reported $332.31M in 2024. The forecast for 2026 is $347.09M, followed by $448.57M for 2027, and $536.8M for 2028.

What is Esperion Therapeutics’s net income forecast?

Esperion Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-4.894M, representing a -90.54% decrease from the reported $-51.745M in 2024. Projections indicate $-3.404M in 2026, $45.88M in 2027, and $76.64M in 2028.